Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Adrenocortical Cancer clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07920198
Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal Disorders Outpatient Clinic of the Clinical Unit of Endocrinology at the Modena University Hospital (AOU Modena)
Primary Objective: The primary objective of the study is to characterize subjects affected by adrenal disease by collecting medical history data at diagnosis, clinical, bio-humoral, and radiological data, as well as information regarding the therapeutic approach, in terms of both potential surgical interventions and/or pharmacological therapies and hormone replacement therapies. Secondary Objective: The secondary objective is to integrate these data with current knowledge in order to improve the clinical, diagnostic, and therapeutic management of patients affected by adrenal disease, as well as to identify risk and/or predisposing factors for the development of the disease. Study Design: Observational, longitudinal, single-center, non-interventional (without drug administration) study. The study is divided into two phases: FIRST PHASE (retrospective): registration of all patients affected by hypothalamic-pituitary-adrenal disease followed by the Adrenal Diseases Outpatient Clinic of the Endocrinology Unit at the AOU of Modena. SECOND PHASE (prospective): enrollment of all patients affected by adrenal disease consecutively presenting to the Adrenal Diseases Outpatient Clinic of the Endocrinology Unit at the AOU of Modena. Study Population Inclusion criteria: subjects affected by adrenal disease presenting to the Adrenal Diseases Outpatient Clinic of the Endocrinology Unit at the AOU of Modena, who are able to autonomously provide written informed consent. Exclusion criteria: subjects under 18 years of age. Study Methodologies An anonymized database will be created to collect data from patients presenting to the aforementioned outpatient clinic. Specifically, the data collected for each patient will include: demographic data, data related to the adrenal disease, symptoms, physical examination, radiological imaging, surgical intervention data, histological examination data, bio-humoral tests, hormonal tests, DEXA data, current replacement therapies data, current anti-secretory medical therapies data, data on other current pharmacological therapies, and comorbidities data.
Gender: All
Ages: 18 Years - Any
Updated: 2026-11-09
1 state
NCT04897321
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the maximum (highest) dose of B7-H3-CAR T cells that are safe to give to patients with B7-H3-positive solid tumors. Primary objective To determine the safety of one intravenous infusion of autologous, B7-H3-CAR T cells in patients (≤ 21 years) with recurrent/refractory B7-H3+ solid tumors after lymphodepleting chemotherapy Secondary objective To evaluate the antitumor activity of B7-H3-CAR T cells Exploratory objectives * To evaluate the tumor environment after treatment with B7-H3-CAR T cells * To assess the immunophenotype, clonal structure and endogenous repertoire of B7-H3-CAR T cells and unmodified T cells * To characterize the cytokine profile in the peripheral blood after treatment with B7-H3-CAR T cells
Gender: All
Ages: Any - 21 Years
Updated: 2026-05-19
1 state